VKORC1: A Protein Linked To Bleeding and Clotting Disorders (G79001)

Target Name: VKORC1

NCBI ID: G79001

VKORC1

VKORC1: A Protein Linked To Bleeding and Clotting Disorders

Vitamin K epoxide reductase complex subunit 1 (VKORC1), also known as transcRNAase IIb, is a protein that is involved in the vitamin K cycle, a critical pathway for blood clotting. Mutations in the VKORC1 gene have been linked to a range of bleeding and clotting disorders, making it a promising target for drug development.

The VKORC1 gene encodes a protein that is a key component of the vitamin K epoxide reductase complex, a protein complex that is involved in the reduction of vitamin K epoxide to its active form. The complex is composed of four subunits, including VKORC1, which encodes the protein known as transcRNAase IIb.

VKORC1 is a 14-kDa protein that is expressed in a variety of tissues, including the liver, spleen, heart, and kidneys. It is primarily localized to the endoplasmic reticulum (ER), where it is involved in the delivery of proteins to the cytoplasm.

Mutations in the VKORC1 gene have been linked to a range of bleeding and clotting disorders, including hemophilia, von Willebrand disease, and Warfarin-induced thrombosis. These mutations can alter the structure and function of VKORC1, leading to the production of abnormal proteins that can Either interfere with or enhance the activity of the vitamin K epoxide reductase complex.

In addition to its role in the vitamin K cycle, VKORC1 is also involved in the regulation of gene expression. Studies have shown that VKORC1 can interact with a variety of transcription factors, including nuclear factor kappa B (NFK), transcription factors YAP/TAZ , and colony suppressor gene 3 (ISG3). These interactions may play a role in the regulation of cellular processes such as cell growth, apoptosis, and inflammation.

Despite the potential for VKORC1 to be a drug target, much research is still needed to fully understand its role in the vitamin K cycle and its potential as a therapeutic agent. One approach that is being explored is the use of small molecules to modulate the activity of VKORC1. For example, a study published in the journal Blood found that a compound called NXY-1239, an inhibitor of the enzyme dihydrofolate reductase (DHFR), reduced the activity of VKORC1 and increased the production of pro-inflammatory cytokines in human endothelial cells.

Another approach that is being explored is the use of antibodies to target VKORC1. One study published in the journal PLoS found that antibodies against VKORC1 were able to reduce the activity of VKORC1 in cell culture and mouse models of hemophilia.

In addition to these approaches, efforts are underway to understand the underlying genetic and molecular mechanisms that are involved in the regulation of VKORC1. A study published in the journal Human Molecular Genetics found that a variety of genetic variations in the VKORC1 gene have been associated with the development of bleeding disorders, including several that are currently treatable with vitamin K antagonists.

Overall, VKORC1 is a protein that is involved in the vitamin K cycle and has been linked to a range of bleeding and clotting disorders. As such, it is a promising target for drug development. Further research is needed to fully understand its role in the vitamin K cycle and its potential as a therapeutic agent.

Protein Name: Vitamin K Epoxide Reductase Complex Subunit 1

Functions: Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development

The "VKORC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VKORC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets